1. Research three to five (3-5) ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety.
Weight: 5%
Did not submit or incompletely researched three to five (3-5) ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety.
Partially researched three to five (3-5) ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety.
Satisfactorily researched three to five (3-5) ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety.
Thoroughly researched three to five (3-5) ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety.
2. Argue for or against Direct-to-Consumer (DTC) marketing by drug companies.
Weight: 5%
Did not submit or incompletely argued for or against Direct-to-Consumer (DTC) marketing by drug companies.
Partially argued for or against Direct-to-Consumer (DTC) marketing by drug companies.
Satisfactorily argued for or against Direct-to-Consumer (DTC) marketing by drug companies.
Thoroughly argued for or against Direct-to-Consumer (DTC) marketing by drug companies.
3. Determine who regulates compounding pharmacies under the current regulatory scheme, what the Food and Drug Administration (FDA) could / should have done in this scenario, and whether the FDA should be granted more power over compounding pharmacies.
Weight: 10%
Did not submit or incompletely determined who regulates compounding pharmacies under the current regulatory scheme, what the Food and Drug Administration (FDA) could / should have done in this scenario, and whether the FDA should be granted more power over compounding pharmacies.
Partially determined who regulates compounding pharmacies under the current regulatory scheme, what the Food and Drug Administration (FDA) could / should have done in this scenario, and whether the FDA should be granted more power over compounding pharmacies.
Satisfactorily determined who regulates compounding pharmacies under the current regulatory scheme, what the Food and Drug Administration (FDA) could / should have done in this scenario, and whether the FDA should be granted more power over compounding pharmacies.
Thoroughly determined who regulates compounding pharmacies under the current regulatory scheme, what the Food and Drug Administration (FDA) could / should have done in this scenario, and whether the FDA should be granted more power over compounding pharmacies.
4a. Decide whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with utilitarianism.
Weight: 5%
Did not submit or incompletely decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with utilitarianism.
Partially decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with utilitarianism.
Satisfactorily decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with utilitarianism.
Thoroughly decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with utilitarianism.
4b. Decide whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with deontology.
Weight: 5%
Did not submit or incompletely decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with deontology.
Partially decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with deontology.
Satisfactorily decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with deontology.
Thoroughly decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with deontology.
4c. Decide whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with virtue ethics.
Weight: 5%
Did not submit or incompletely decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with virtue ethics.
Partially decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with virtue ethics.
Satisfactorily decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with virtue ethics.
Thoroughly decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with virtue ethics.
4d. Decide whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with ethics of care.
Weight: 5%
Did not submit or incompletely decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with ethics of care.
Partially decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with ethics of care.
Satisfactorily decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with ethics of care.
Thoroughly decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with ethics of care.
4e. Decide whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with your own moral / ethical compass.
Weight: 5%
Did not submit or incompletely decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with your own moral / ethical compass.
Partially decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with your own moral / ethical compass.
Satisfactorily decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with your own moral / ethical compass.
Thoroughly decided whether PharmaCARE’s use of Colberian intellectual property would be ethical in accordance with your own moral / ethical compass.
5. Analyze the way PharmaCARE uses U.S. law to protect its own intellectual property while co-opting intellectual property in Colberia.
Weight: 5%
Did not submit or incompletely analyzed the way PharmaCARE uses U.S. law to protect its own intellectual property while co-opting intellectual property in Colberia.
Partially analyzed the way PharmaCARE uses U.S. law to protect its own intellectual property while co-opting intellectual property in Colberia.
Satisfactorily analyzed the way PharmaCARE uses U.S. law to protect its own intellectual property while co-opting intellectual property in Colberia.
Thoroughly analyzed the way PharmaCARE uses U.S. law to protect its own intellectual property while co-opting intellectual property in Colberia.
6. Suggest at least three (3) ways the company could compensate the people and nation of Colberia for the use of its intellectual property and the damage to its environment.
Weight: 10%
Did not submit or incompletely suggested at least three (3) ways the company could compensate the people and nation of Colberia for the use of its intellectual property and the damage to its environment.
Partially suggested at least three (3) ways the company could compensate the people and nation of Colberia for the use of its intellectual property and the damage to its environment.
Satisfactorily suggested at least three (3) ways the company could compensate the people and nation of Colberia for the use of its intellectual property and the damage to its environment.
Thoroughly suggested at least three (3) ways the company could compensate the people and nation of Colberia for the use of its intellectual property and the damage to its environment.
7. Compare PharmaCARE’s actions with those of at least one (1) real-world company whose creativity in skirting legal technicalities led to ethical lapses and financial loss.
Weight: 10%
Did not submit or incompletely compared PharmaCARE’s actions with those of at least one (1) real-world company whose creativity in skirting legal technicalities led to ethical lapses and financial loss.
Partially compared PharmaCARE’s actions with those of at least one (1) real-world company whose creativity in skirting legal technicalities led to ethical lapses and financial loss.
Satisfactorily compared PharmaCARE’s actions with those of at least one (1) real-world company whose creativity in skirting legal technicalities led to ethical lapses and financial loss.
Thoroughly compared PharmaCARE’s actions with those of at least one (1) real-world company whose creativity in skirting legal technicalities led to ethical lapses and financial loss.
8. Determine the success PharmaCARE and WellCo shareholders would have in suits against the companies.
Weight: 5%
Did not submit or incompletely determined the success PharmaCARE and WellCo shareholders would have in suits against the companies.
Partially determined the success PharmaCARE and WellCo shareholders would have in suits against the companies.
Satisfactorily determined the success PharmaCARE and WellCo shareholders would have in suits against the companies.
Thoroughly determined the success PharmaCARE and WellCo shareholders would have in suits against the companies.
9. Determine whether or not PharmaCARE lives up to its brand. Support the response.
Weight: 5%
Did not submit or incompletely determined whether or not PharmaCARE lives up to its brand. Did not submit or incompletely supported the response.
Partially determined whether or not PharmaCARE lives up to its brand. Partially supported the response.
Satisfactorily determined whether or not PharmaCARE lives up to its brand. Satisfactorily supported the response.
Thoroughly determined whether or not PharmaCARE lives up to its brand. Thoroughly supported the response.
10. Recommend at least three (3) changes PharmaCARE can make to be more ethical going forward.
Weight: 5%
Did not submit or incompletely recommended at least three (3) changes PharmaCARE can make to be more ethical going forward.
Partially recommended at least three (3) changes PharmaCARE can make to be more ethical going forward.
Satisfactorily recommended at least three (3) changes PharmaCARE can make to be more ethical going forward.
Thoroughly recommended at least three (3) changes PharmaCARE can make to be more ethical going forward.
